Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
In the case of Novo Nordisk, which as a Danish company reports its financials in Danish kroner rather than U.S
10.2337/db16-1009 Summary Keywords GLP-1 receptor agonist, molecular mechanisms, gut microbiota, multi-organ protection, therapeutic repurposing Citation Gong B, Li C, Shi Z, Wang F, Dai R, Chen G and Su H (2025) GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy
The obesity/chronic weight management segment is expected to grow at the fastest CAGR during the forecast period, fueled by growing awareness of obesity as a chronic illness and rising obesity rates worldwide
95% CI 1.98 to 1.50
US$ 20.55
US$ 21.01
US$ 20.21
US$ 29.55
